Nicholas Caselli

Nick represents public companies, boards and executives in high-stakes securities, shareholder and M&A litigation. He defends securities class actions and derivative suits, litigates M&A disputes and shareholder demands, and advises on corporate governance and litigation risk. Nick is one of the few litigators nationwide to have taken a securities case to a federal jury trial and secured a complete defense verdict. He has litigated several novel and precedent-setting securities and shareholder issues to victory in federal trial and appellate courts and in the Delaware Court of Chancery and Delaware Supreme Court. He regularly represents innovative companies in the technology, life sciences, fintech and crypto industries.

Nick was named the New York Law Journal’s 2026 Rising Star in securities and shareholder litigation and recognized by The Legal 500 as an “emerging talent” in the field. He clerked for Judge Matthew W. Brann of the US District Court for the Middle District of Pennsylvania.

Nick’s recent representations include:

• A leading data and AI software company in a securities class action concerning growth, efficiencies, revenue targets and operations*
• A leading crypto company in a securities class action concerning key client relationships and revenue breakdowns*
• A late-stage clinical biopharmaceutical company in a securities class action concerning its clinical trials and lead drug candidate*
• A life sciences company in a securities class action concerning the efficacy of its childhood lead-testing devices*
• A leading medical products company in a securities class action concerning the spinoff and integration of its animal health business*
• A global biopharmaceutical company in a Delaware Court of Chancery controlling stockholder challenge following the spinoff and acquisition of a subsidiary*
• A Dutch technology company in a securities class action concerning forecasting*
• A lithium-ion battery recycling company in a securities class action concerning its recycling methods and financial reporting*
• A global pharmaceutical company in a securities class action concerning vaccine efficacy claims*
• Eleven major global financial institutions in a securities class action concerning the underwriting of a healthcare company’s initial public offering*
• A used vehicle consignment and remarketing company in a securities class action concerning its business model, partnerships, inventory and unit economics*
• A major multinational food corporation in a securities class action concerning COVID-19 safety protocols at its facilities*
• A major multinational media company in a Delaware Court of Chancery action seeking an anti-arbitration injunction and enforcement of its forum clause*
• The world’s leading association for corporate governance professionals as amicus curiae before the US Supreme Court in a securities class action concerning disclosure sufficiency*

* Representation handled before joining Cooley